We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PASG icon
176
Passage Bio
PASG
$14.4M
$677K 0.05%
3,392
-3,901
-53% -$930K
MITO
177
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$651K 0.05%
478,561
-9,453
-2% -$12.8K
IRD
178
Opus Genetics
IRD
$306M
$608K 0.04%
118,063
-1,488
-1% -$6.86K
SRPT icon
179
Sarepta Therapeutics
SRPT
$1.57B
$602K 0.04%
+6,496
New +$500K
SEEL
180
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$589K 0.04%
64
-9
-12% -$77.3K
KLDO
181
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$546K 0.04%
+100,000
New +$620K
LRMR icon
182
Larimar Therapeutics
LRMR
$397M
$545K 0.04%
47,193
-5,775
-11% -$69.3K
RLMD icon
183
Relmada Therapeutics
RLMD
$557M
$544K 0.04%
20,743
-279,464
-93% -$7.48M
AGEN
184
Agenus
AGEN
$312M
$542K 0.04%
5,258
-33
-0.6% -$3.73K
BGMS
185
Bio Green Med Solution Inc
BGMS
$4.91M
$524K 0.04%
28
– –
INMB icon
186
INmune Bio
INMB
$46.5M
$517K 0.04%
26,632
-120,251
-82% -$2.32M
ICPT
187
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$513K 0.04%
34,565
-435
-1% -$6.96K
DCTH icon
188
Delcath Systems
DCTH
$422M
$468K 0.03%
44,857
+942
+2% +$9.29K
HYFT
189
MindWalk Holdings
HYFT
$60.6M
$459K 0.03%
73,882
-76,118
-51% -$518K
OTIC
190
DELISTED
Otonomy, Inc.
OTIC
$399K 0.03%
208,306
-3,165
-1% -$5.37K
EYPT icon
191
EyePoint Inc
EYPT
$1.03B
$380K 0.03%
36,427
-83,708
-70% -$798K
GNCA
192
DELISTED
Genocea Biosciences, Inc.
GNCA
$377K 0.03%
196,821
-3,179
-2% -$6.25K
PBYI icon
193
Puma Biotechnology
PBYI
$404M
$349K 0.02%
49,843
-5,058
-9% -$37.9K
ORTX
194
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$341K 0.02%
14,813
-187
-1% -$5.56K
WHWK
195
Whitehawk Therapeutics
WHWK
$190M
$335K 0.02%
11,408
-100,332
-90% -$3.06M
MREO
196
Mereo BioPharma
MREO
$54.7M
$322K 0.02%
903,680
-40,628
-4% -$108K
ASLN
197
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$288K 0.02%
35,434
+4,821
+16% +$548K
ALNY icon
198
Alnylam Pharmaceuticals
ALNY
$27.5B
$276K 0.02%
+1,461
New +$274K
NVAX icon
199
Novavax
NVAX
$1.2B
$266K 0.02%
1,283
-1,353
-51% -$298K
COGT icon
200
Cogent Biosciences
COGT
$6.65B
$258K 0.02%
30,727
-11,035
-26% -$84.6K
6 7
8
9 10

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.